ClinicalTrials.Veeva

Menu

Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments

K

Kaohsiung Veterans General Hospital

Status and phase

Enrolling
Phase 4

Conditions

Vomiting
Postoperative Complications
Respiratory Depression
Constipation
Postoperative Nausea

Treatments

Drug: Propofol
Drug: Remimazolam

Study type

Interventional

Funder types

Other

Identifiers

NCT06777758
KSVGH24-CT8-16

Details and patient eligibility

About

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

Full description

Objective This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

Methods The investigators will conduct a prospective, randomized, single-center study. Eligible patients will be randomly allocated into three groups: the first group receiving Propofol alone for moderate sedation anesthesia (control group), the second group receiving Remimazolam alone for anesthesia, and the third group receiving a combination of Propofol and Remimazolam for anesthesia. The investigators will record anesthesia depth (DSA values of BIS), heart rate, blood pressure, oxygen saturation, and other indicators during the procedure, as well as postoperative recovery time, time to consciousness recovery, oxygen desaturation, instances of inadequate anesthesia depth, intraoperative patient movement or recall, surgeon satisfaction, patient satisfaction, readmission rate within 14 days, complications, and length of hospital stay.

Enrollment

90 estimated patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects are between 20-80 years old.
  • Anesthesiologists rated ASA as between I and III.
  • Patients undergoing upper gastrointestinal endoscopic examination or therapy.

Exclusion criteria

  • Allergy to Propofol, Remimazolam, or opioid medications.
  • Emergency surgery.
  • Pregnancy.
  • History of malignant hyperthermia.
  • Impaired liver or kidney function.
  • Airway difficulties due to pharyngeal tumors.
  • Refusal to participate.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

90 participants in 3 patient groups

Propofol
Active Comparator group
Description:
The patient underwent a routine upper gastrointestinal endoscopy.
Treatment:
Drug: Propofol
Remimazolam
Experimental group
Description:
The patient underwent routine upper gastrointestinal endoscopy and Remimazolam was substituted for Propofol.
Treatment:
Drug: Remimazolam
Propofol + Remimazolam
Experimental group
Description:
The patient underwent routine upper gastrointestinal endoscopy, and the anesthetic drug used was Propofol combined with Remimazolam.
Treatment:
Drug: Remimazolam
Drug: Propofol

Trial contacts and locations

1

Loading...

Central trial contact

Chen-Hsiu Chen, Ph.D; Yuan-Yi Chia, M.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems